Table 2.
Baseline serum biochemistry in the SCaRF trial by treatment arm
| Variable | Total (N = 31) | CC (n = 11) | SH + SC (n = 20) | Reference interval |
|---|---|---|---|---|
| Phosphate, mmol/l | 1.41 (0.40) | 1.49 (0.46) | 1.37 (0.37) | 0.75–1.50 |
| Calcium, mmol/l | 2.18 (0.22) | 2.10 (0.18) | 2.22 (0.23) | 2.10–2.60 |
| Albumin, g/l | 32 (3) | 32 (2) | 33 (4) | 35–50 |
| Bicarbonate, mmol/l | 24 (2) | 24 (2) | 25 (2) | 22–32 |
| Magnesium, mmol/l | 0.92 (0.15) | 0.86 (0.15) | 0.93 (0.14) | 0.7–1.10 |
| Intact PTH, pmol/l | 51 (33, 67) | 48 (33, 67) | 54 (31, 63) | 1.7–10.0 |
| ALP, IU/ml | 118 (90, 164) | 115 (90, 164) | 118 (89, 159) | 30–110 |
| T50, min | 274 (67) | 271 (60) | 275 (73) | 270–460 |
| CRP, mg/l | 5 (2, 8) | 6 (2, 8) | 5 (2, 9) | <5 |
ALP, alkaline phosphatase; CC, calcium carbonate; PTH, parathyroid hormone; SC, sevelamer carbonate; SCaRF, Sevelamer Versus Calcium to Reduce Fetuin-A-containing Calciprotein Particles in Dialysis; SH, sevelamer hydrochloride; T50, serum calcification propensity.
Data are expressed as mean (SD) or median (25th, 75th percentile).